This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Thank you. Good morning and thanks for joining us. I am Sapna Srivastava, biotech analyst at Goldman Sachs. And it’s my pleasure to host Craig Wheeler, CEO of Momenta. And thank you so much Craig for coming, really appreciate to know with the trip (indiscernible) with the morning here.
Before we go into the discussion, I just want to read this out to the audience. We’re required to make certain disclosures and public appearances about Goldman Sachs’ relationships with companies that we discuss. The disclosures relate to investment banking relationships’ compensation received or 1% or more ownership. I am prepared to read disclosures if anyone would like me to, however, these disclosures are available in our most recent reports available to U.S. clients on our firm’s portals. Views of non-Goldman Sachs personnel may not represent the company views.
And with that, I will kick it off, and just a reminder to the audience we would like this to be interactive. So please ask as many questions as you have. Craig, when we sat down here last year, it’s amazing to me how much has happened at Momenta since then, from the Lovenox side of it to the Baxter side of it. I would just love to get your views over like, this really I think a period of massive activity and evolution of the company, where do you see your most – your largest key opportunities now and where you are most focused for taking the company towards?